Test Code SP5TS Septin-5 Antibody, Tissue Immunofluorescence Titer, Serum
Specimen Required
Only orderable as a reflex. For more information see MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum.
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Detecting septin-5 IgG in serum specimens
Reporting an end titer result from serum specimens
Testing Algorithm
If the indirect immunofluorescence pattern suggests septin-5, then septin-5 antibody cell-binding assay and this test will be performed at an additional charge.
Method Name
Only orderable as a reflex. For more information see MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum.
Indirect Immunofluorescence Assay (IFA)
Reporting Name
Septin-5 IFA Titer, SSpecimen Type
SerumSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
Septin-5 IgG is a biomarker of a rapidly progressive, but treatable, form of autoimmune cerebellar ataxia. Patients present with subacute onset of cerebellar ataxia with prominent eye movement symptoms (oscillopsia or vertigo). Improvement may occur after immunotherapy.
Reference Values
Only orderable as a reflex. For more information see MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum.
<1:240
Interpretation
Seropositivity for septin antibodies by indirect immunofluorescence is consistent with a diagnosis of autoimmune disease of the central nervous system. Cell-binding assay testing for septin-5 IgG is required to confirm the diagnosis.
Cautions
Negative results for septin antibodies do not exclude neurological autoimmunity or cancer.
Day(s) Performed
Monday through Sunday
Report Available
5 to 10 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86256
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
SP5TS | Septin-5 IFA Titer, S | 101458-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
616113 | Septin-5 IFA Titer, S | 101458-8 |